Neoadjuvant immunotherapy in non-small-cell lung cancer: Times are changing—and fast

Recent data from a phase 3 trial have shown that the addition of immunotherapy to neoadjuvant chemotherapy improves event-free survival in patients with non-small-cell lung cancer (NSCLC). This is the first positive phase 3 trial in this setting, although several phase 3 trials are currently investi...

Descripción completa

Detalles Bibliográficos
Autores principales: Aguado, Carlos, Maestre, Unai Jiménez, Mielgo-Rubio, Xabier
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Baishideng Publishing Group Inc 2022
Materias:
Letter to the Editor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9537502/
https://www.ncbi.nlm.nih.gov/pubmed/36212602
http://dx.doi.org/10.5306/wjco.v13.i9.758
_version_ 1784803215451095040
author Aguado, Carlos
Maestre, Unai Jiménez
Mielgo-Rubio, Xabier
author_facet Aguado, Carlos
Maestre, Unai Jiménez
Mielgo-Rubio, Xabier
author_sort Aguado, Carlos
collection PubMed
description Recent data from a phase 3 trial have shown that the addition of immunotherapy to neoadjuvant chemotherapy improves event-free survival in patients with non-small-cell lung cancer (NSCLC). This is the first positive phase 3 trial in this setting, although several phase 3 trials are currently investigating the efficacy of neoadjuvant and adjuvant immunotherapy in resectable NSCLC.
format Online
Article
Text
id pubmed-9537502
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Baishideng Publishing Group Inc
record_format MEDLINE/PubMed
spelling pubmed-95375022022-10-08 Neoadjuvant immunotherapy in non-small-cell lung cancer: Times are changing—and fast Aguado, Carlos Maestre, Unai Jiménez Mielgo-Rubio, Xabier World J Clin Oncol Letter to the Editor Recent data from a phase 3 trial have shown that the addition of immunotherapy to neoadjuvant chemotherapy improves event-free survival in patients with non-small-cell lung cancer (NSCLC). This is the first positive phase 3 trial in this setting, although several phase 3 trials are currently investigating the efficacy of neoadjuvant and adjuvant immunotherapy in resectable NSCLC. Baishideng Publishing Group Inc 2022-09-24 2022-09-24 /pmc/articles/PMC9537502/ /pubmed/36212602 http://dx.doi.org/10.5306/wjco.v13.i9.758 Text en ©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved. https://creativecommons.org/licenses/by-nc/4.0/This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial.
spellingShingle Letter to the Editor
Aguado, Carlos
Maestre, Unai Jiménez
Mielgo-Rubio, Xabier
Neoadjuvant immunotherapy in non-small-cell lung cancer: Times are changing—and fast
title Neoadjuvant immunotherapy in non-small-cell lung cancer: Times are changing—and fast
title_full Neoadjuvant immunotherapy in non-small-cell lung cancer: Times are changing—and fast
title_fullStr Neoadjuvant immunotherapy in non-small-cell lung cancer: Times are changing—and fast
title_full_unstemmed Neoadjuvant immunotherapy in non-small-cell lung cancer: Times are changing—and fast
title_short Neoadjuvant immunotherapy in non-small-cell lung cancer: Times are changing—and fast
title_sort neoadjuvant immunotherapy in non-small-cell lung cancer: times are changing—and fast
topic Letter to the Editor
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9537502/
https://www.ncbi.nlm.nih.gov/pubmed/36212602
http://dx.doi.org/10.5306/wjco.v13.i9.758
work_keys_str_mv AT aguadocarlos neoadjuvantimmunotherapyinnonsmallcelllungcancertimesarechangingandfast
AT maestreunaijimenez neoadjuvantimmunotherapyinnonsmallcelllungcancertimesarechangingandfast
AT mielgorubioxabier neoadjuvantimmunotherapyinnonsmallcelllungcancertimesarechangingandfast

Ejemplares similares